N@N

MYRIAD GENETICS INC (NASDAQ:MYGN), Down By 19.97% ($4.83) From $24.190 After BUYINS.NET Report Predicted Stock Would Go Down Du

^{Published on 2011-08-04 05:31:38 - WOPRAI}
 

August 4, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, June 15th 2011 stating that MYRIAD GENETICS INC (NASDAQ:MYGN) was expected to go Down due to the Bearish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=mygn&id=172784

At the time this story was written, MYRIAD GENETICS INC (NASDAQ:MYGN) is Down By $4.83 (19.97%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

MYRIAD GENETICS INC (NASDAQ:MYGN) - Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine products. The company markets BRACAnalys for the treatment of hereditary breast and ovarian cancer; COLARIS molecular for hereditary colorectal and uterine cancer; COLARIS AP for the treatment of hereditary colon cancer; and MELARIS to treat hereditary melanoma. It also offers TheraGuide 5-FU for chemotherapy toxicity to 5-FU; PREZEON that assess PTEN status for disease progression and drug response; OnDose, a personalized medicine product to measure chemotherapy exposure to 5-FU; Prolaris to treat prostate cancer; and Panexia for the treatment of pancreatic and related cancer. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net